Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis

<div>GMG-ITC treatment modulates innate and acquired immune response. In brain sections, TLR-4 detection reveals immunopositivity in untreated SOD1tg rats (a), while SOD1tg rats treated with GMG-ITC show negative staining for TLR4 (b). In untreated SOD1tg rats the immunopositivity of brain sections to CD8 antibody identified wide areas with infiltrating cells (c). GMG-ITC treatment reveals the capability to counteract the release of cytotoxic T cells at level of brain sections (d).</div>

BioMed Research International

fig6

Figure 6

Figure 6: Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 

Figure 6 | Administration of 4-(α-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1G93A Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 